With shares of Facebook (NYSE:FB) trading around $24, is FB an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s Movement
Facebook is engaged in building products to create utility for users, developers, and advertisers. People use Facebook to stay connected with their friends and family, to discover what is going on in the world around them, and to share and express what matters to them to the people they care about. Developers can use the Facebook Platform to build applications and websites that integrate with Facebook to reach its global network of users and to build personalized and social products. Advertisers can engage with more than 900 million monthly active users on Facebook or subsets of its users based on information they have chosen to share. Social networking has been a powerful movement and tool in recent years that has changed the way many companies and consumers operate. Facebook is a pioneer and a leader in the social network trend that looks to be here to stay. Facebook will see rising profits through its engagement with the increasing user base that social networking is seeing in coming years.
Top 5 Warren Buffett Stocks To Invest In Right Now: Analogic Corp (ALOG)
Analogic Corporation (Analogic), incorporated in November 27, 1967, is a technology company that designs and manufactures advanced medical imaging and security systems and subsystems sold to Original Equipment Manufacturers (OEMs) and end users primarily in the healthcare and airport security markets. Analogic operate primarily three segments: Medical Imaging, Ultrasound, and Security Technology. Medical Imaging, which primarily includes systems and subsystems for computed tomography (CT) and magnetic resonance imaging (MRI) medical imaging equipment, Selenium-based detectors for screening and diagnostic applications in mammography. Ultrasound, which designs, manufactures, and distributes ultrasound systems and transducers primarily in the urology, surgery, robotic assisted surgery, anesthesia, and general imaging markets. Security Technology, which includes advanced threat detecting CT systems. In March 2013, it completed the acquisition of Ultrasonix Medical Corporation. In September 2013, the Company announced that it has acquired the remaining ownership stake in PocketSonics, Inc.
Medical Imaging
During the fiscal year ended July 31, 2012 (fiscal 2012), the Company�� medical imaging segment, which accounted for approximately 59% of its net revenue, which consists primarily of electronic systems and subsystems for medical imaging, sold globally to OEM producers of CT, MRI, and digital mammography systems. Products under this consist of: X-Ray Detectors, which converts the x-ray energy in a CT machine to useful analog signals for processing in the DAS.
DAS, which are used to process the signals created by the detectors and feed them as a digital stream to a reconstruction computer to create high resolution images. The DAS is designed with many multi-channel circuit boards that process the analog signals from the detectors and convert them into digital signals through an array of analog to digital.
converters. DMS, which the brains of the CT sys! tem and consists of both the detector array and the DAS in one package. This system provides its OEM customers a level of integration that allows for lower cost and faster time to market. Integrated Gantries, which is a component of the CT system (detectors, DAS, x-ray tube and power supplies), are mounted on a rotating ring assembly called a gantry. It provides integrated gantries to its OEM customers as another level of integration.
For OEM producers of MRI equipment, it also supplies two key components: gradient amplifiers and radio frequency, or RF, amplifiers. It has developed a range of amplifier solutions for its customers ranging from low-magnetic-field systems (< 0.3 Tesla) to ultra high-field systems (> 7.0 Tesla) used in academic research hospitals.
Gradient Amplifier, which is a power systems used to drive a set of coils located inside the MRI system and around the patient. The coils energize the atomic structure of patients��anatomy in order to develop tissue and structure images. Gradient amplifiers must be specifically designed for different MRI field strengths ranging from 0.3 Tesla to >7.0 Tesla. RF Amplifiers, which is a power systems used to control another set of the coils within the MRI system that are used to read-back the signals from the anatomy generated by the gradient coils. These signals are then processed in a reconstruction computer to create images. The RF amplifiers must have a high signal-to-noise ratio to produce the cleanest images.
The Company�� digital mammography products consist primarily of digital mammography selenium-based x-ray detector plates, sold directly to OEM customers for screening and diagnostic applications in mammography. These x-ray detector plates are used by OEMs in mammography systems to convert x-ray signals into high resolution two-dimensional (2-D) and three-dimensional (3-D) images of breast tissue to aid in the detection of breast cancer. Its detector plates for mammography applications are sold to! medical ! OEMs for use in products worldwide. Its mammography product portfolio consists of: LMAM, which is its large area detector plate, based on selenium technology, is used primarily for European markets and was recently introduced in the United States market. This detector plate is also compatible with systems that can perform tomosynthesis, which creates 3-D images through a series of exposures to more accurately detect lesions in the breast. SMAM, which is its small area detector plate uses the same selenium-based technology as the LMAM detector and is manufactured primarily for the Asian markets. Within its medical imaging segment, it also designs and manufactures precision motion control systems, which it supplies to OEM customers for use in computer-controlled automation systems primarily in the semiconductor and medical markets.
Ultrasound
The Company�� ultrasound segment designs and manufactures procedure-driven ultrasound systems and transducers, principally under the B-K Medical brand. These products are primarily for end-user markets in urology and surgery and accounted for approximately 29% of its net revenue in fiscal year 2012. Its ultrasound systems use acoustic waves to generate real-time images of the body�� internal anatomy that are used for interventional and medical diagnostic procedures. These ultrasound systems are also used for guiding robotic assisted surgical procedures and for guiding prostate cancer treatment employing a procedure called brachytherapy. It also manufactures and sells advanced ultrasound probes and transducers to medical OEMs.
Security Technology
Utilizing the Company�� CT technology, its Security Technology segment designs and manufactures airport security systems and subsystems primarily for checked bag applications and accounted for approximately 12% of its net revenue in fiscal year 2012. These systems generate 3-D images of objects contained within baggage and provide threat analysis of materials conta! ined with! in the bags. The Company sells the checked baggage systems through L-3 Communications Corporation (L-3): eXaminer XLB (High Speed), eXaminer 3DX (Medium Speed) and eXaminer SX (Reduced Size).
The Company competes with General Electric Corporation (GE) and Koninklijke Philips Electronics N.V. (Philips), Hitachi Medical Corporation, Fujifilm, Morpho Detection and Science Applications International Corp. (SAIC).
Advisors' Opinion:- [By Steven Russolillo]
WATCH FOR:�May ADP Jobs Survey (8:15 a.m. Eastern Time): seen +210K; previously +220K. April US Trade Deficit (8:30): seen $40.9B; previously $40.4B. First Quarter Productivity (8:30, second read): seen -3.1%; previously -1.7%. First Quarter Unit Labor Costs (8:30, second read): seen +5.5%: previously +4.2%. May ISM Non-Manufacturing PMI (10:00): seen 55.2; previously 55.2. Analogic(ALOG), Ciena(CIEN), Cooper, Diamond Foods(DMND), J.M. Smucker(SJM), Joy Global(JOY), Piedmont Natural Gas(PNY), UTi Worldwide, Vail Resorts, Vera Bradley(VRA) and VeriFone(PAY) are among companies scheduled to report quarterly results.
- [By Roland Head]
General Motors stock is also likely to be in demand when markets open after the company announced last night that it will replace H.J. Heinz in the S&P 500 following Heinz's recent sale to Warren Buffett's Berkshire Hathaway, which is expected to close on Friday. General Motors stock is 2.7% higher in premarket trading. (NASDAQ: ALOG )
- [By John Udovich]
Small cap security stocks Analogic Corporation (NASDAQ: ALOG), OSI Systems, Inc (NASDAQ: OSIS) and View Systems Inc (OTCBB: VSYM) all aid Big Brother to keep us safe with security inspection systems intended for airports and other public�places rather than equipment to just spy on us. Moreover, the security inspection systems market is global and massive as its not just about detecting potential hijackers at airports as such systems can be used to fight or prevent crime. With that thought in mind, here is a look at three small cap security inspection system stocks:
- [By Wallace Witkowski]
Shares of Analogic Corp. (ALOG) �fell 12% to $85 on light volume after the electronics-component maker reported fiscal second-quarter earnings of $1.17 a share on revenue of $141.4 million and forecast flat revenue for the year because of headwinds. Analysts expected $1.20 a share on revenue of $151.7 million, along with a 7% revenue growth for the year.
5 Best Building Product Stocks To Own Right Now: Amarin Corporation PLC(AMRN)
Amarin Corporation Plc, a clinical-stage biopharmaceutical company, focuses on developing treatments for cardiovascular diseases. Its lead product candidate includes AMR101, a prescription grade omega-3 fatty acid, which is in second Phase III clinical trial for the treatment of high triglyceride levels in statin-treated patients who have mixed dyslipidemia. The company, formerly known as Ethical Holdings plc, was founded in 1989 and is based in Dublin, Ireland.
Advisors' Opinion:- [By Quoth the Raven]
Amarin (AMRN) continues to barrel forward - with each week's prescription data behind it, Amarin proves wrong everyone (including myself) who said they'd really have a tough go of it getting Vascepa prescriptions out there without the help of a major pharmaceutical partner. This past week's data showed a small, cyclical stall in total prescriptions and a promising week-over-week gain in refills.
- [By Keith Speights]
Disappointing status quo
Sometimes the most disappointing news is no news at all. That's the story for Amarin (NASDAQ: AMRN ) . Shares dropped 11% as investors appeared to experience a bit of malaise. - [By James E. Brumley]
If you're looking for a potential trade to kick off the new (though shortened) trading week, then put Amarin Corporation plc (NASDAQ:AMRN) at the top of your watchlist. Though it's been working on a turnaround for a few weeks, today may well be the day AMRN actually gets all the way over the hump and turns into a reliable mover.
- [By Brian Orelli]
Amarin (NASDAQ: AMRN ) , for example, nearly doubled after announcing data for a phase 3 trial testing its lipid-lowering drug, Vascepa. While investors expected the drug to lower triglyceride levels, they got a nice surprise when the drug also lowered bad LDL cholesterol, especially since its direct competitor, GlaxoSmithKline's (NYSE: GSK ) Lovaza, increases bad cholesterol.
5 Best Building Product Stocks To Own Right Now: Acorda Therapeutics Inc.(ACOR)
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS with walking disability under the Fampyra name internationally. Its lead research and development programs include three biologic therapeutic approaches for restoring neurologic and cardiac function, which comprise Neuregulin Program for developing Glial Growth Factor 2, a molecule in the Phase I clinical trial for the treatment of heart failure; Remyelina ting Antibodies Program for developing rHIgM22, an antibody in the preclinical stage for treating MS; and Chondroitinase Program, a research stage program focused on developing chontroitinase as a therapeutic to break down inhibitory factors in the scar tissue that develops as a result of an injury to the CNS. In addition, the company has in-licensed a clinical-stage program, AC105, to develop an acute treatment for neurological trauma. It has collaboration agreement with Biogen Idec International GmbH to develop and commercialize products containing aminopyridines to the treatment of MS. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Hawthorne, New York.
Advisors' Opinion:- [By RichardCox]
With any rally, some examples of over-extension can be found. One stock to sell on the short side can be seen in Acorda Therapeutics (ACOR), which to some will look cheap with its low P/E ratio of 9.6. Looking at the fundamentals, product stories some potential obstacles. Looking at the walk-test data in the company's central offering (Ampyra) have been largely uninspiring. Because of this, further Phase IIb trials will likely be required before we can see a move into Phase III. This will almost certainly stall the development process - by as much as 2 years. This story will continue to drag on projections and create downward revisions in both sales growth and earnings projections and sales growth. Upside potential for this stock remains limited, and short selling opportunities await on any rallies:
- [By Ben Levisohn]
Acorda Therapeutics (ACOR) has dropped today after announcing the results of a clinical trial.
Getty ImagesFrom Accorda’s press release:
Acorda Therapeutics, Inc. today announced data from a Phase 2 proof-of-concept study of dalfampridine extended release tablets, 10 mg (dalfampridine-ER) in people with post-stroke deficits. In the study, treatment with dalfampridine-ER was well-tolerated and improved walking, as measured by the Timed 25-Foot Walk test (T25FW).
RBC Capital Markets’ Michael Yee and team put the news in context:
In the short-term, ACOR’s scripts look a bit mediocre tracking a tad shy of Q3 consensus, and overall new scripts are down too. Longerterm, we believe value creation will need to come from 1) expanding the label to a new indication in “post-stroke” pts which is going into Phase II/III and could theoretically double the commercial sales, 2) its re-myelinating antibody rHigM22 in Phase I might get attention because Biogen’s Phase II LINGO re-myelinating program could be very intriguing in H2:14. Risks are that a Paragraph IV should be expected in January 2014 around the corner and the “post-stroke” data is interesting but not as compelling versus the MS indication. Overall, however this will take some time to play out as the next post-stroke study doesn’t even begin until Q2:14 so data not until at least 2015+. That said, expectations are pretty low and we think the stock is pretty cheap at $1.1B EV or ~3x sales plus all potential upside from label expansion or pipeline.
MannKind (MNKD), meanwhile, has gained after asking the FDA to approve its inhaled diabetes drug Afrezza. The Associated Press has the details:
MannKind has no drugs on the market. It first filed for Food and Drug Administration approval of Afrezza in March 2009, and in early 2011 the FDA told the company to run more clinical studies. The agency wanted MannKind to use the stu
- [By Sean Williams]
What: Shares of Acorda Therapeutics (NASDAQ: ACOR ) , a commercial-stage biopharmaceutical company with a focus on central nervous system disorders, jumped as much as 13% after the company reported positive phase 2 trial data for experimental drug Ampyra for the treatment of post-stroke deficits.
- [By Eric Volkman]
Acorda Therapeutics (NASDAQ: ACOR ) today announced its selection of a new�CFO. Michael Rogers replaces David Lawrence, who has been named chief of business operations. �
5 Best Building Product Stocks To Own Right Now: Sotherly Hotels Inc (SOHO)
SoTHERLY Hotels Inc., formerly MHI Hospitality Corporation, incorporated on August 2004, is a self-managed and self-administered real estate investment trust (REIT) that was formed to own, acquire, renovate and reposition primary full-service upper upscale and upscale hotel properties located in primary markets in the Mid-Atlantic and Southern United States. The Company conducts its business through MHI Hospitality, L.P., its operating partnership, of which the Company is the general partner. As of December 31, 2011, the Company owned approximately 77% of the partnership units in its operating partnership. In November 2013, SoTHERLY Hotels Inc announced that it has acquired the entity which owns the Crowne Plaza Houston Downtown Hotel, a 259-room, upscale, full-service hotel located in downtown Houston, Texas.
As of March 1, 2012, the Company�� portfolio consisted of 10 primarily full-service up-scale and upper up-scale hotels located in seven states with an aggregate of 2,424 rooms and approximately 120,200 square feet of meeting space. Nine of these hotels are wholly owned by subsidiaries of its operating partnership and operate under the Hilton Worldwide, InterContinental Hotels Group and Starwood Hotels and Resorts brands and are managed on a day to day basis by MHI Hotels Services, LLC (MHI Hotels Services). It also owns a 25% indirect non-controlling interest in the Crowne Plaza Hollywood Beach Resort through a joint venture with Carlyle.
The Company leases its hotel properties to MHI Hospitality TRS, LLC (its TRS Lessee), which in turn has engaged MHI Hotels Services, an independent management company, to manage its hotels. Its TRS Lessee is a wholly owned subsidiary of MHI Hospitality TRS Holding, Inc. (MHI Holding, and collectively, MHI TRS). As of March 1, 2012, the Company�� portfolio consisted of the properties, including Crowne Plaza Hampton Marina, Crowne Plaza Tampa Westshore , Crowne Plaza Jacksonville Riverfront , Crowne Plaza Jacksonville Riverfront , ! DoubleTree by Hilton Brownstone - University and Holiday Inn Laurel West. As of December 31, 2011, the Company owns two leasehold interests in the Shell Island Resort, a 160-unit condominium resort property in Wrightsville Beach, North Carolina
Advisors' Opinion:- [By George Putnam]
Steve Halpern: Now, another pick that you have is Sotherly Hotels (SOHO). Could you tell us about that company?
George Putnam: Sure. This is a small-cap name. Like many others in the industry, it had to struggle a bit from 2008 and has devoted most of its attention to getting its balance sheet back in order, and some of its existing hotels fixed-up and repositioned.
- [By Marc Bastow]
Upscale hotel property real estate investment trust Sotherby (SOHO) raised its quarterly dividend 12.5% to 4.5 cents per share, payable on Jan. 1, 2014 to shareholders of record as of Dec. 13.
SOHO Dividend Yield:�3.87%
No comments:
Post a Comment